ArticleCancer research communications2026
Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti-PD-1 Antibody.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Immune checkpoint inhibitors have improved outcomes in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), yet reliable biomarkers predicting response to programmed death 1 (PD-1) blockade remain limited. We retrospectively analyzed 40 patients with R/M HNSCC treated with nivolumab or pembrolizumab monotherapy, evaluating clinical data, laboratory parameters, PD-L1 expression, tumor-infiltrating T cells, and peripheral immune features. Peripheral blood mononuclear cells obtained before treatment were assessed by flow cytometry for exhaustion markers and short-term tumor antigen-derived peptide stimulation with IFN-γ ELISA. The objective response rate was 18%, with median overall survival of 13 months and progression-free survival of 3 months. PD-L1 expression and densities of CD4+, CD8+, and FoxP3+ T cells were not associated with response. In contrast, responders more frequently developed immune-related adverse events and had preserved cervical lymph nodes. Favorable responses were associated with higher baseline lymphocyte and lower neutrophil percentages, as well as lower frequencies of CD38+ CD8+ T cells. Notably, c-Met-derived peptide stimulation induced significantly higher IFN-γ production in responders, indicating the presence of circulating tumor antigen-reactive T cells. These findings suggest that tumor antigen-reactive T cells, together with a favorable systemic immune profile, are associated with clinical benefit from PD-1 blockade and that peripheral blood-based peptide-reactive T-cell assays may provide a practical approach for biomarker development in R/M HNSCC. SIGNIFICANCE: c-Met-specific circulating tumor antigen-reactive T cells predict response to PD-1 blockade in R/M HNSCC. Favorable systemic immunity further supports outcomes. Peripheral blood-based assays offer a practical, noninvasive biomarker to identify patients most likely to benefit from immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.